Project Grant R15CA277656
Award Date
8/8/23
Completion Date
7/31/26
Dollars Obligated
$462K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Wisconsin, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) for the development of an engineered prodrug that leverages tumor-associated hyperactive membrane-anchored serine proteases to selectively deliver potent cytotoxins to cancer cells. The goal is to create a more effective therapeutic strategy for treating metastatic and recurrent solid tumors, including ovarian, lung, and colon cancers....
The University of Wisconsin-Milwaukee (UWM) was awarded a $793,378 Project Grant by the U.S. Department of Energy's Office of Science Financial Assistance Program (CFDA 81.049) to conduct research on the effects of low-dose radiation on breast tissue using fibroblasts and mammographic density models. The project, titled "Automated High Throughput Screening of the Effect of Low-Dose Radiation on Breast Using Fibroblasts Incorporated Mammographic Density Models," aims to advance...
The National Cancer Institute (NCI) awarded the University of Alabama at Birmingham (UAB) a $585,228 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop a novel antibody-drug conjugate (ADC) platform. The grant, titled "The Resurgence of Antibody-Drug Conjugates via PMPC-Polymer Engineering," aims to enhance the anti-cancer efficacy and overcome the limitations of existing ADCs. The key products and services to be delivered under this 5-year grant include: Confirming the...
The Medical College of Wisconsin, Inc. was awarded a $935,999 Project Grant from the Defense Health Agency on April 15, 2023 to complete work by April 14, 2027. The grant is part of the agency's Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative solutions for battlefield medicine and other priorities. Specifically, this award will fund research into...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $474,547 to support research focused on targeting metabolic vulnerabilities of cancer stem cells in triple negative breast cancer (TNBC). The research aims to examine the feasibility of using a pro-oxidant compound, IB-DNQ, alone or in combination with inhibition of the SOD1 enzyme, to effectively target cancer stem cells across the epithelial-mesenchymal transition spectrum in TNBC....
The University of Wisconsin-Madison will receive $1,377,598 under a three-year Project Grant from the Defense Health Agency to investigate medical solutions for targeting dysregulated histone-modifying enzymes driving prostate cancer cell survival after androgen deprivation therapy. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield...
This $1,251,230.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports breast cancer research at the University of Wisconsin - Madison. The award will fund a clinical trial over a 4-year period from June 2025 to June 2029, involving a Breakthrough Award - Funding Level 3 with a Partnering Principal Investigator option. The research aims to transform healthcare for military service members and the broader public...
The University of Miami was awarded a $538,553 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct longitudinal research on imaging and liquid biopsy markers to predict outcomes for prostate cancer patients receiving radiotherapy. The 5-year project aims to define the role of quantitative multiparametric MRI features and circulating tumor cells in predicting biochemical and clinical disease progression, with the goal of developing...
The Medical College of Wisconsin, Inc. (MCW) was awarded a $1,046,468 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2023, will fund research to investigate chemotherapy dosing in obese patients, with the goal of optimally balancing risks and benefits to avoid overtreatment and undertreatment. The research will be conducted at MCW's facilities in Milwaukee, WI and is expected to be completed by...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,242,611.36 in funding to The Medical College of Wisconsin, Inc. to study the role of the chemokine ligand CCL24 in promoting metastasis of aggressive estrogen receptor-negative breast cancer. The key research objectives are: 1) To determine the clinical significance of CCL24 expression in breast cancer and its induction of epithelial-to-mesenchymal transition (EMT) leading to...